We observed persistent thrombocytopenia predicts thrombotic risk in antiphospholipid syndrome (APS) patients. Well-managed obstetric APS patients reached a successful outcome in 80% of pregnancies. We described differential lymphocyte phenotype profiles to discriminate between Sjgren's and Sicca syndromes. In inflammatory myopathies we described how to classify and manage their diagnosis in adult patients. We identified biomarkers in idiophatic and inherited angioedema for phenotype classification. We found gene and molecular signatures in scleroderma and vasculitis improve clinic stratification of these patients. In a long-term follow up study, we described angiogenic and cardivascular risk factors in pre-eclamptic pregnancies. In patients with bioimplants, we found a haplotype as a risk factor for developing autoimmune disorders. Finally, we studied immune mechanisms involved in thrombosis in COVID-19 patients with antiphospholipid antibodies and their risk of developing Long-Covid.
Group Leader
Jaume Alijotas Reig
Principal Investigator (PI)
Francesc Miró Mur, Albert Selva O’Callaghan, Carmen Pilar Simeón Aznar, Roser Solans Laqué, Josep Pardos Gea, Moisés Labrador Horrillo, Segundo Buján Rivas, Mar Guilarte Clavero, Victòria Cardona Dahl
Researchers
Anna Sala Cunill, Alfredo Guillén del Castillo, Olga Luengo Sánchez, Fernando Martínez Valle, Jaume Mestre Torres, Enrique Esteve Valverde
PhD Students
Ariadna Anunciación Llunell, Joana Marques Soares
Lab Technicians
Daniel Granados Pino
81
PUBLICATIONS
532
IMPACT FACTOR
6.57
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Anunciación-Llunell A, Miró-Mur F, Esteve-Valverde E, Marques-Soares J, Pardos-Gea J, Alijotas-Reig J
Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review
Autoimmun Rev . 2021 Dec;20(12):102982.
DOI: DOI: 10.1016/j.autrev.2021.102982
IF: 9.75
Sala-Cunill A, Luengo O, Curran A, Moreno N, Labrador-Horrillo M, Guilarte M, González-Medina M, Galván-Blasco P, Cardona V
Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial
Allergy . 2021 May;76(5):1507-1516.
DOI: DOI: 10.1111/all.14626
IF: 13.15
Callejas-Moraga EL, Guillén-Del-Castillo A, Perurena-Prieto J, Sanz-Martínez MT, Fonollosa-Pla V, Lorite-Gomez K, Severino A, Bellocchi C, Beretta L, Mahler M, Simeón-Aznar CP
Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis
Rheumatology (Oxford) . 2021 Dec 24;61(1):154-162
DOI: DOI: 10.1093/rheumatology/keab279
IF: 7.58
Orozco-Gálvez O, Fernández-Codina A, Simó-Perdigo M, Pinal-Fernández Y, Martínez-Valle F
Response to Treatment in IgG4-Related Disease Assessed by Quantitative PET/CT Scan
Clin Nucl Med . 2021 Jun 1;46(6):e307-e311.
DOI: DOI: 10.1097/RLU.0000000000003537
IF: 7.79
Selva-O'Callaghan A, Simeón-Aznar CP
The scleromyositis phenotype. Lessons from a multicentre international cohort of anti-PM/Scl-positive patients
Rheumatology (Oxford) . 2021 Nov 3;60(11):4956-4957.
DOI: DOI: 10.1093/rheumatology/keab433
IF: 7.58
Design of an integrative patient stratification approach for the systemic sclerosis management.
Principal Investigator: Carmen Pilar Simeón Aznar
Agency: Marató TV3
Funding: 72,250 €
Period: 2021-2023
Identificación de biomarcadores celulares y moleculares en angioedema idiopático y hereditario para su diferenciación en fenotipos y endotipos.
Principal Investigator: Mar Guilarte Clavero
Agency: Instituto de Salud Carlos III
Funding: 84,700 €
Period: 2021-2023
Trastorns autoimmunes i al·loimmunes i la seva relació amb trastorns reproductius
Principal Investigator: Jaume Alijotas Reig
Agency: Private funding: Fundació ONA Futura
Funding: 135,000€
Period: 2021-2023
Physiopathological basis of the systemic manifestations of long COVID
Principal Investigator: Jaume Alijotas Reig
Agency: Fundació Althaia
Funding: 16,000€
Period: 2021-2022
